Animal models and
clinical trials have shown that antioxidants and anti-inflammatory drugs could not only reduce
symptoms associated with the disorders but also prevent the appearance of neurobiological abnormalities and transition to psychosis if given early
during brain development.
For screening and
clinical management, and for
clinical trials, it would be extremely useful to be able to monitor the pathological progression of Alzheimer's disease (AD), especially
during the decades preceding the onset of
clinical symptoms when AD spreads silently in the brain.